Equillium, Inc. (EQ)

NASDAQ: EQ · IEX Real-Time Price · USD
0.635
+0.005 (0.84%)
Jun 5, 2023, 1:06 PM EDT - Market open
0.84%
Market Cap 21.86M
Revenue (ttm) 24.64M
Net Income (ttm) -28.95M
Shares Out 34.41M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 114,958
Open 0.630
Previous Close 0.630
Day's Range 0.630 - 0.650
52-Week Range 0.480 - 3.200
Beta 1.20
Analysts Strong Buy
Price Target 6.50 (+923.46%)
Earnings Date May 11, 2023

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2018
Employees 37
Stock Exchange NASDAQ
Ticker Symbol EQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EQ stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 923.46% from the latest price.

Price Target
$6.5
(923.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

4 days ago - Business Wire

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #celiacdisease--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therape...

3 weeks ago - Business Wire

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

3 weeks ago - Business Wire
}

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to ...

1 month ago - Business Wire

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

2 months ago - Business Wire

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis...

2 months ago - Business Wire

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato...

3 months ago - Business Wire

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

4 months ago - Business Wire
}

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

5 months ago - Business Wire

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

5 months ago - Business Wire

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

6 months ago - Business Wire

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

6 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Equillium, Inc.

NEW YORK,, Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. ("Equillium" or the "Co...

Other symbols: MTCR
6 months ago - PRNewsWire
}

SHAREHOLDER ALERT: Weiss Law Investigates Metacrine, Inc.

NEW YORK , Nov. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Metacrine, Inc. ("Metacrine" or the "Co...

Other symbols: MTCR
6 months ago - PRNewsWire

Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

7 months ago - Business Wire

Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders...

7 months ago - Business Wire

Equillium to Present at Two Upcoming Investor Conferences

LA JOLLA, Calif.

7 months ago - Business Wire

METACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Metacrine Inc....

8 months ago - Business Wire

Equillium's stock is up 12% after sharing early data about its investigational lupus treatment

Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 ...

8 months ago - Market Watch

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders w...

8 months ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, MTCR, STOR, RCKT

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache...

Other symbols: MTCRRCKT
9 months ago - PRNewsWire